Johnson & Johnson (NYSE:JNJ - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18, Zacks reports. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson updated its FY 2025 guidance to 10.500-10.700 EPS.
Johnson & Johnson Trading Up 2.3 %
JNJ traded up $3.51 during trading on Friday, hitting $157.42. The company's stock had a trading volume of 10,972,370 shares, compared to its average volume of 7,945,892. The stock has a market cap of $379.37 billion, a PE ratio of 23.67, a PEG ratio of 2.56 and a beta of 0.49. The firm's 50 day moving average price is $159.49 and its 200-day moving average price is $154.99. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.30%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several research analyst reports. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $171.82.
Get Our Latest Analysis on Johnson & Johnson
Insider Buying and Selling
In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.
Institutional Trading of Johnson & Johnson
An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,876 shares of the company's stock after buying an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent reporting period. 69.55% of the stock is currently owned by institutional investors.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
